OAC1 是一种有效的Oct4激活剂。OAC1 激活 Oct4 和 Nanog 启动子，促进诱导多功能干细胞 (iPSC) 的形成。OAC1 通过上调 HOXB4 表达激活 OCT4。OAC1 增加了 Oct4-Nanog-Sox2 三联体和 Tet1 的转录。OAC1 通过提高效率和缩短重编程时间，促进了细胞的重编程。
| 生物活性 | OAC1 is a potentOct4activator. OAC1 activates Oct4 and Nanog promoters and enhances induced pluripotent stem cells (iPSC) formation. OAC1 activates OCT4 through upregulation of HOXB4 expression. OAC1 increases transcription of the Oct4-Nanog-Sox2 triad and Tet1. OAC1 facilitates the reprogramming of cells by enhancing efficiency and shortening the reprogramming time[1][2]. |
体外研究
(In Vitro) | OAC1 (10 μM; 7 d) enhances reprogramming efficiency. OAC1 increases induced pluripotent stem cells (iPSC) generation from mouse embryonic fibroblasts (MEFs) and accelerates the appearance of iPSC-like colonies[1].
OAC1 (1 μM; 2 d; human IMR90 fibroblast cells) activates endogenous Oct4, Nanog, Sox2, and Tet1 expression[1].
OAC1 (500 nM; 4 d; CD34+cells) increases numbers of phenotypic hematopoietic stem cells (HSC) and functional Hematopoietic progenitor cells (HPC)[2].
OAC1 (500 nM; 4 d; CD34+cells) activates OCT4 through upregulation of HOXB4 expression to expand hematopoietic stem cells (HSC)[2].
Cell Proliferation Assay[2] | Cell Line: | CD34+cells from human cord blood | | Concentration: | 500 nM | | Incubation Time: | 4 days | | Result: | Increased the numbers of CD34+CD38-cells.
Increased the number of Lin-CD34+CD38-CD45RA-CD90+CD49f+cells.
Increased in the number of phenotypic hematopoietic stem cells (HSC) compared to control vectors.
Enhanced expansion of HPC with both full and suboptimal cytokine doses in the expansion and colony forming phases. |
|
体内研究
(In Vivo) | OAC1 (50000 CB CD34+cells with OAC1(500 nM); i.h.; 16 weeks) enhances short and long-term engrafting hematopoietic stem cells (HSC) in irradiated NSG mice[2].
| Animal Model: | Irradiated NSG mice with OAC1 or vehicle control treated CB CD34+cells within 24h after irradiation[2] | | Dosage: | 16 weeks | | Administration: | Subcutaneous injection OAC1(500 nM) treated CB CD34+cells | | Result: | Increased cord blood (CB) cells in primary recipients, compared to the vehicle control group, with the board increase for human B cells, T cells, and myeloid cells in the bone marrow (BM) of primary recipients, resulting in a significant expansion of SRC numbers. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : ≥ 40 mg/mL(168.59 mM) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 4.2148 mL | 21.0739 mL | 42.1479 mL | | 5 mM | 0.8430 mL | 4.2148 mL | 8.4296 mL | | 10 mM | 0.4215 mL | 2.1074 mL | 4.2148 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (10.54 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.54 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (10.54 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.54 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 3. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (10.54 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.54 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com